Company intelligence / Profile preview

GC Cell

Yongin-si, Gyeonggi-do, Koreagccell.com ↗

Ownership: Private
Development stage: Commercial

Overview

GC Cell has commercialized Immuncell-LC, an autologous CIK & CTL therapy approved in Korea since 2007 for adjuvant treatment of hepatocellular carcinoma. The company is advancing a robust pipeline of allogeneic NK and CAR-NK cell therapies targeting various cancers, with several candidates in preclinical to early clinical stages. Over 10,000 patients have been treated with their solid tumor therapy.

Therapeutic areas: OncologyImmunology
Modalities: Autologous cell therapies (CIK, CTL)Allogeneic NK cell therapiesCAR-NK cell therapies
Industry: Biotech

Drug pipeline

5 assets

immuncell-lc

4 more assets in the full pipeline.

Request access →

Partnerships

Artiva BiotherapeuticsBioCentriq

Beyond the preview

Go deeper on GC Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC Cell.

Explore the full profile